mass spectrometry comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-02-24. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
Receptor-binding studies classify melanotan II as a non-selective melanocortin agonist. It interacts with MC1R, MC3R, MC4R and MC5R, with reported affinities in the low nanomolar range and no strong subtype preference. Activation of MC1R on dermal melanocytes shifts pigment synthesis toward eumelanin, the dark polymer deposited in melanosomes and transferred to keratinocytes. Because the same peptide engages MC4R in the hypothalamus, it also appears in animal work on food intake and erectile response, which is why it is discussed in both pigment and metabolic research. Which receptor populations dominate after systemic exposure in humans is not fully established.
Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
epidemic in the 2000s is related to a number of factors. Rates of opioid use and dependency vary by age, sex, race, and socioeconomic status. With respect to race, the discrepancy in deaths is thought to be due to an interplay between physician prescribing and lack of access to healthcare and certain prescription drugs. Men are at higher risk for opioid use and dependency than women, and men also account for more opioid overdoses than women, although this gap is closing. Women are more likely to be prescribed pain relievers, be given higher doses, use them for longer durations, and become dependent upon them faster. Deaths due to opioid use also tend to skew at older ages than deaths from use of other illicit drugs. This does not reflect opioid use as a whole, which includes younger people. Overdoses from opioids are highest among people between the ages of 40 and 50, in contrast to heroin overdoses, which are highest among people between the ages of 20 and 30. 21- to 35-year-olds represent 77% of people who enter treatment for opioid use disorder, but the average age of first-time use of prescription painkillers was 21.2 years in 2013. Among the middle class, means of acquiring funds include elder financial abuse and international dealers noticing a lack of enforcement in their transaction scams throughout the Caribbean.
t1/2: Biological half-life tmax: Time to achieve maximum plasma concentration pKi: the measurement of ligand binding affinity Methylnaltrexone bromide has poor oral bioavailability, and for that reason, every other day it is administered subcutaneously. About half of the dose is excreted in the urine and somewhat less in feces with 85% eliminated unchanged. Alvimopan has considerable low bioavailability (6%) due to its high binding affinity and low dissociation rate. Essentially, alvimopan is mediated by biliary secretion with an average plasma clearance of 400 ml/min. Metabolism of alvimopan is via intestinal flora resulting in hydrolysis of alvimopan to the active amide metabolite (ADL 08-0011). However, the metabolite is considered clinically irrelevant due to its low binding affinity. When naloxegol is given with a fatty meal, absorption increases. Clearance is mostly via hepatic metabolism (P450-CYP3A) with unknown actions of the metabolites. Naloxegol has small fragments eliminated by renal excretion. Naldemedine metabolites mainly via CYP3A to nor-naldemedine, it also metabolites via UDP-glucuronosyltransferase 1A3 to naldemedine 3-G, but in a lesser extent. Those metabolites are both opioid receptor antagonists but are less potent than the parent compound.
Neoplasm: benign or malignant Granuloma: tuberculosis Infection: round pneumonia Vascular: infarct, varix, granulomatosis with polyangiitis, rheumatoid arthritis There are a number of features that are helpful in suggesting the diagnosis:
=== Conditionality === The general principle of conditionality is expressed in numerous early sources as "When this is, that is; This arising, that arises; When this is not, that is not; This ceasing, that ceases." According to Rupert Gethin, this basic principle is neither a direct Newtonian-like causality nor a singular form of causality. Rather, it asserts an indirect and plural conditionality which is somewhat different from classic European views on causation. The Buddhist concept of dependence is referring to conditions created by a plurality of causes that necessarily co-originate phenomena within and across lifetimes, such as karma in one life creating conditions that lead to rebirth in a certain realm of existence for another lifetime. Bhikkhu Bodhi writes that the Buddhist principle of conditionality "shows that the "texture" of being is through and through relational." Furthermore, he notes that dependent arising goes further than just presenting a general theory about conditionality, it also teaches a specific conditionality (idappaccayatā), which explains change in terms of specific conditions. Dependent arising therefore also explains the structure of relationships between specific types of phenomena (in various interlocking sequences) which lead to suffering as well as the ending of suffering.
Those men that were stigmatic were non-ordained, including Saint Francis. Harrison argues that in many cases the stigmata was a consequence of the intense personal mystical ministries practiced by those excluded from the priesthood. Only in the twentieth century have cases of stigmatic priests appeared. One suggestion is that painful bruising syndrome may explain rare cases of non self-induced stigmata. Skeptical investigator Joe Nickell who investigated recent cases of stigmata such as Katya Rivas, as well as stigmatics throughout history, commented that the cases are indistinguishable from hoaxing. In 2002, a psychoanalytic study of stigmatic Therese Neumann suggested her stigmata resulted from post-traumatic stress symptoms expressed in unconscious self-mutilation through abnormal autosuggestibility. According to a study of the French theologian Joachim Bouflet, in the 21st century there were 200 stigmatics all over the world. Most of them reached the third age without having particular health problems. The oldest stigmatic was Marie-Julie Jahenny who died in 1941 at the age of 91. As of 1997, the stigmatics who had been declared saints by the Roman Catholic Church were only 7.
Sources: en.wikipedia.org
Radioactive decay results in a reduction of summed rest mass, once the released energy (the disintegration energy) has escaped in some way. Although decay energy is sometimes defined as associated with the difference between the mass of the parent nuclide products and the mass of the decay products, this is true only of rest mass measurements, where some energy has been removed from the product system. This is true because the decay energy must always carry mass with it, wherever it appears (see mass in special relativity) according to the formula E = mc2. The decay energy is initially released as the energy of emitted photons plus the kinetic energy of massive emitted particles (that is, particles that have rest mass). If these particles come to thermal equilibrium with their surroundings and photons are absorbed, then the decay energy is transformed to thermal energy, which retains its mass. Decay energy, therefore, remains associated with a certain measure of the mass of the decay system, called invariant mass, which does not change during the decay, even though the energy of decay is distributed among decay particles. The energy of photons, the kinetic energy of emitted particles, and, later, the thermal energy of the surrounding matter, all contribute to the invariant mass of the system. Thus, while the sum of the rest masses of the particles is not conserved in radioactive decay, the system mass and system invariant mass (and also the system total energy) is conserved throughout any decay process.
The optimal ranges for estrogen apply only to individuals taking estradiol (or an ester of estradiol), and not to those taking synthetic or other non-bioidentical preparations (e.g., conjugated estrogens or ethinylestradiol). Physicians also recommend broader medical monitoring, including complete blood counts; tests of renal function, liver function, and lipid and glucose metabolism; and monitoring of prolactin levels, body weight, and blood pressure. If prolactin levels are greater than 100 ng/mL, estrogen therapy should be stopped and prolactin levels should be rechecked after 6 to 8 weeks. If prolactin levels remain high, an MRI scan of the pituitary gland to check for the presence of a prolactinoma should be ordered. Otherwise, estrogen therapy may be restarted at a lower dosage. Cyproterone acetate is particularly associated with elevated prolactin levels, and discontinuation of cyproterone acetate lowers prolactin levels. In contrast to cyproterone acetate, estrogen and spironolactone therapy is not associated with increased prolactin levels.
List of things named after Adrien-Marie Legendre Associated Legendre polynomials Gauss–Legendre algorithm Legendre's constant Legendre's equation in number theory Legendre's functional relation for elliptic integrals Legendre's conjecture Legendre sieve Legendre symbol Legendre's theorem on spherical triangles Saccheri–Legendre theorem Least squares Least-squares spectral analysis Seconds pendulum From Summetria to Symmetry: The Making of a Revolutionary Scientific Concept
=== Iodine === Iodine is used in chemistry as an indicator for starch. When starch is mixed with iodine in solution, an intensely dark blue colour develops, representing a starch/iodine complex. Starch is a substance common to most plant cells and so a weak iodine solution will stain starch present in the cells. Iodine is one component in the staining technique known as Gram staining, used in microbiology. Used as a mordant in Gram's staining, iodine enhances the entrance of the dye through the pores present in the cell wall/membrane. Lugol's solution or Lugol's iodine (IKI) is a brown solution that turns black in the presence of starches and can be used as a cell stain, making the cell nuclei more visible. Used with common vinegar (acetic acid), Lugol's solution is used to identify pre-cancerous and cancerous changes in cervical and vaginal tissues during "Pap smear" follow up examinations in preparation for biopsy. The acetic acid causes the abnormal cells to blanch white, while the normal tissues stain a mahogany brown from the iodine.
Sources: en.wikipedia.org
The convention elected a national committee of 33 members, with 22 seats for the majority caucus, 8 seats for Harrington's Coalition Caucus, 2 for the Debs caucus, and one for the "independent" Samuel H. Friedman. These minority caucuses all opposed the name change. The convention voted on and adopted proposals for its program by a two-one vote, with the majority caucus winning every vote.
=== Year-round production === Because hydroponic crops can be grown indoors in controlled environments, crops are not dependent on growing seasons or climate. Additionally, extreme weather conditions such as drought and freezing temperatures are less impactful to crops. This stabilizes production and allows hydroponics to produce crops more consistently year-round than traditional farming.
Busby WH, Quackenbush GE, Humm J, Youngblood WW, Kizer JS (1987). "An enzyme(s) that converts glutaminyl-peptides into pyroglutamyl-peptides. Presence in pituitary, brain, adrenal medulla, and lymphocytes". J. Biol. Chem. 262 (18): 8532–6. doi:10.1016/S0021-9258(18)47446-7. PMID 3597387. Fischer WH, Spiess J (1987). "Identification of a mammalian glutaminyl cyclase converting glutaminyl into pyroglutamyl peptides". Proc. Natl. Acad. Sci. U.S.A. 84 (11): 3628–32. Bibcode:1987PNAS...84.3628F. doi:10.1073/pnas.84.11.3628. PMC 304928. PMID 3473473. Messer M; Ottesen M (1965). "Isolation and properties of glutamine cyclotransferase of dried papaya latex". C. R. Trav. Lab. Carlsberg. 35 (1): 1–24. PMID 5846578.
Climate change is projected to raise average temperatures in Portugal by as much as 3–4 °C (37.4–39.2 °F) by 2100 relative to the 1990s–2010s average, with impacts in water, ecosystem, agriculture, health, and security.
In a retail market that is decriminalized such as in The Netherlands, where wholesale production is illegal but prosecutions are not always enforced because of the contradiction of the law that is recognised by the courts, competition puts pressure on breeders to create increasingly attractive varieties to maintain market share. Breeders give their strains distinct and memorable names in order to help differentiate them from their competitors' strains, although they may in fact be very similar.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
Only a small number of early-stage human studies have been reported, and most were limited in size and duration. No large late-stage program has established a general efficacy or safety profile. The evidence base is therefore thin compared with approved medicines.